On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...
In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...
A unique peek inside the human brain may help explain how it clears away waste like the kind that can build up and lead to ...
Scientists have uncovered a mechanism in the brain that explains how drugs like methamphetamine and PCP impair cognitive ...
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
"As the drug has already been approved, it doesn't have to undergo a complex approval procedure and could soon supplement the standard therapy for this deadly brain tumor." Glioblastoma is rare ...
A new drug has been approved ... new class of medications for the brain disorder in several decades, according to a press release. "Today’s landmark approval of our first-in-class treatment ...
No new treatments for schizophrenia have been approved ... brain while tamping it down elsewhere in the body. He and his team tested 7,000 compounds and eventually combined xanomeline with a drug ...
Today, the Food and Drug Administration approved the first new type of drug ... treat psychosis act on the same chemical that helps the brain communicate with the rest of the body - dopamine.
A new drug has been approved for the treatment of schizophrenia ... This marks the first new class of medications for the brain disorder in several decades, according to a press release.